- UK authorisation and launch occurred in June and July 2026.
- NHS England describes restricted, rather than routine, tablet access.
- Wegovy tablets and Rybelsus should not be treated as substitutes.
Three milestones, three different meanings
The MHRA authorised Wegovy tablets for adult weight management on 11 June 2026. Novo Nordisk’s UK announcement records a launch on 6 July. These are distinct milestones: authorisation allows a medicine to be marketed for its licensed use, while launch indicates commercial introduction.
NHS access is a further question. In a letter dated 10 September, NHS England said oral Wegovy was not routinely available through the NHS in England. It identified an exception where an integrated care board had decided to commission treatment for a defined group. Private availability should therefore not be interpreted as a promise of an NHS prescription.
In Scotland, advice published by the Scottish Medicines Consortium on 12 October did not recommend the tablets because the manufacturer had not made a submission. That decision should not be confused with its separate advice on injectable Wegovy.
Tablets have their own instructions
The UK product information specifies a daily tablet taken after a recommended fast of at least eight hours. It must be swallowed whole with up to 120 ml of water, followed by a wait of at least 30 minutes before food, drink or other oral medicines. These requirements affect absorption and deserve attention when discussing whether a routine is workable.
A tablet may appeal to someone who would prefer to avoid injections, but that preference is only one consideration. Prescribers also need to assess health history, current medicines, possible adverse effects and the person’s ability to follow the regimen. Neither delivery method guarantees a particular result.
Do not confuse oral semaglutide products
NHS England also warned that Rybelsus and oral Wegovy should not be used as substitutes for one another. Both contain semaglutide, but its letter states that NHS commissioning of Rybelsus is for type 2 diabetes, not weight management.
The practical question is therefore about the exact product and service: which licensed formulation is being prescribed, under which eligibility rules, and with what ongoing care? The English commissioning letter should not be presented as a single rule for all four UK nations. Current local arrangements and national guidance remain relevant.
Sources & further reading
These links support the information above; they do not imply endorsement of this website.
- MHRA: Wegovy tablet authorisation, 11 June 2026
- Novo Nordisk UK: Wegovy tablet launch announcement, 6 July 2026
- NHS England: prescribing and supply of oral semaglutide, 10 September 2026
- Wegovy tablets UK Summary of Product Characteristics
- Scottish Medicines Consortium: oral Wegovy advice published 12 October 2026
Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.
Read our editorial standards →
Compare prices